logo

Stock Code

600673 SH

1558.HK

Research and Development

At HEC Pharmaceutical Research Institute, we combine world-class expertise, cutting-edge platforms, and global partnerships to translate discovery into therapies that change lives.

HEC Pharmaceutical Research Institute

A state-of-the-art R&D hub driving global pharmaceutical innovation and rapid industrialization.

  • Founded:2005
  • Lab Size:50,000 m² with full R&D capabilities
  • Investment:Over $2.8B USD
  • Collaborations:Top global pharma partners
  • Therapeutic Areas:Infectious, Oncology, Metabolic
  • Product Focus:Generics, Innovative formulations
  • Standards:EU & USA compliant trials
  • Team & Equipment:Diverse experts & world-class tools
KEY STATISTICS
National Key Laboratory
0
The National Key Laboratory for the Development of Anti-Infection New Drugs, responsible for the development of 25 major national projects.
Major Platforms
0
Small Molecule R&D Platform, Large Molecule Development Platform, and Generic Drugs & Innovative Formulations Platform, with complete independent R&D capabilities.
GMP Certifications
0
Holding six GMP certifications from the USA, EU, China, WHO, Australia, and Belarus, forming an internationally recognized pharmaceutical manufacturing system.
Countries and Regions
0+
Serving customers across five continents, 15+ countries and regions, establishing a global sales network layout.
Type-I New Drug Products with Full Intellectual Property
0
28 products in clinical stages, 6 in Phase III clinical trials, 4 having completed overseas Phase I clinical trials, and 1 FDA Orphan Drug Designation.
Ongoing Projects
0+
43 Type-I New Drugs (33 Chemical Innovative Drugs, 10 Biologic Innovative Drugs), 8 Biosimilars, and 50+ Generic Drugs & Reformulated New Drug Projects.
Approved Foreign Patents
0+
Applied Patents
0+

HEC Ecosystem

A powerhouse advancing global healthcare through cutting-edge R&D and seamless industrialization.

Global R&D & Markets

  • Frontier R&D in Infections, Oncology & Chronic Diseases
  • Industrialized Series: Oseltamivir Phosphate, Macrolide Antibiotics, Benzbromarone
  • EU & USA standard clinical trials
  • Advanced fermentation & formulation technologies

Product Highlights

Oseltamivir Phosphate

Global first-line for influenza; pediatric Kwei Granules patented until 2026. Included in national Category B insurance; sales projected> $1.4B.

Macrolide Antibiotics

Leading fermentation process with > 65% global share. Azithromycin covered by 20+ German insurers; Clarithromycin holds 40%+ U.S. market share.

The Power Behind Our Innovation

R&D Team

20+ returnee experts, 100+ PhDs & 1,000+ master's holders

Patents

1,500+ foreign; top-ranked in China for quality & growth

12-Acre Lab

20 LC-MS, 2 NMR & 400+ HPLC; world-class equipment & databases

GLOBAL FOOTPRINT

Formulation Expansion

8First-to-market generics
6Approvals to date
31Products approved in US
28Products approved in EU

Azithromycin covered by 20+ German insurers

Clarithromycin holds 40%+ US market share

Biologics Pipeline

2025Glargine insulin US launch
2026Aspart insulin US launch

4thcompany globally, 1st Chinese to launch insulin in US

Investment & IPO

¥20B RMBSeries A valuation (2021)
Backing from top global institutions
IPO advancement underway